Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development
December 19, 2011
-
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
-
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
-
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
-
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
-
BUSINESS MTPC to Focus on Development of Global Human Resources
December 14, 2011
-
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
-
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
-
REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
-
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
-
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
-
BUSINESS Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
-
BUSINESS Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
-
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
-
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
-
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
-
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
-
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
-
BUSINESS UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
-
REGULATORY CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…